Studies related to CD4 Lymphocytes and Chromium

Chromium Picolinate For Insulin Resistance In Subjects With HIV Disease: A Pilot Study

Effect None
Trial Design Non-controlled trial
Trial Length 1-6 months
Number of Subjects 8
Sex Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
In persons with HIV (where drug therapy is associated with increased risk for insulin resistance) given supplemental chromium at 1mg daily as picolinate, supplementation was associated with a 25% increase in glucose disposal rate as assessed by hyperinsulinaemic–euglycaemic insulin clamp.

There was no influence on viral titres or lymphocytes, and two persons experienced increases in liver enzymes (relationship to chromium uncertain).